The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The fusion between EWS and ETS family members is a key oncogenic event in Ewing tumors and important EWS-FLI1 target genes have been identified. However, until now, the search for EWS-FLI1 targets has been limited to promoter regions and no genome-wide comprehensive analysis of in vivo EWS-FLI1 binding sites has been undertaken. Using a ChIP-Seq approach to investigate EWS-FLI1-bound DNA sequences in two Ewing cell lines, we show that this chimeric transcription factor preferentially binds two types of sequences including consensus ETS motifs and microsatellite sequences. Most bound sites are found outside promoter regions. Microsatellites containing more than 9 GGAA repeats are very significantly enriched in EWS-FLI1 immunoprecipitates. Moreover, in reporter gene experiments, the transcription activation is highly dependent upon the number of repeats that are included in the construct. Importantly, in vivo EWS-FLI1-bound microsatellites are significantly associated with EWS-FLI1-driven gene activation. Put together, these results point out the likely contribution of microsatellite elements to long-distance transcription regulation and to oncogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Long distance EWS-FLI1 binding on GGAA microsatellites results in significant gene expression activation. A. Proportion of EWS-FLI1-bound regions, as compared to the proportion of random regions, around EWS-FLI1 regulated genes. The proportion of EWS-FLI1-bound regions as a function of the distance to the transcription start sites of EWS-FLI1-up or -down regulated genes (solid lines) is shown. As a control, a similar function is indicated for 1500 randomly chosen regions (dashed line). B. Gene Set Enrichment Analysis (GSEA) of genes flanking EWS-FLI1-bound microsatellites. The 94 genes flanking the 80 microsatellites>9R regions (upper panel) as well as the 144 genes flanking the non-microsatellites regions (lower panel) were used as gene set. The expression dataset resulted from previously described EWS-FLI1 inhibition experiments of A673 and SK-N-MC Ewing cell lines [37], [40], ranked using the signal-to-noise algorithm. A strong enrichment of genes flanking EWS-FLI1 bound GGAA microsatellites among EWS-FLI1 up-regulated genes is observed (upper panel). C–F. Regions upstream of EWS-FLI1 up-regulated genes are enriched in GGAA-microsatellites. The number of microsatellites with either 3 to 9 GGAA repeats (grey line) or more than 9 repeats (black line) was calculated for each 1 Kb window from 1 Kb to 1 Mb upstream of the transcription start sites. The numbers of GGAA repeats along DNA are shown for (C) 17000 known genes (control distribution), (D) 582 EWS-FLI1-up-regulated genes, (E) 558 EWS-FLI1-down-regulated genes and (F) 561 genes that are expressed in A673 and SK-N-MC cell lines but not regulated by EWS-FLI1. The control distribution shown in C is also indicated on part D, E and F.](https://figures.cochat.ai/paper-figures/c0718adfd5cb4a83a3b4880138c3629e/the-oncogenic-ews-fli1-protein-binds-in-vivo-ggaa-microsatellite-sequences-with-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ChIP-chip and ChIP-Seq have identified the genomic regions bound by the most common ETS fusion proteins in Ewing’s sarcoma, EWS-FLI1 and EWS-ERG (62, 133, 137).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [137]
In the citing paper
“In fact, four or more repeats are necessary for EWS-FLI1 transcriptional activation in reporter assays, and two EWS-FLI1 monomers bind to this four-motif array in biochemical assays (Figure 7) (133, 137, 187).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Fitting a mixture model by expectation maximization to discover motifs in biopolymers.
Bailey, T. L., & Elkan, C. (1994) · PubMed · Cited by 5,806
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 1×
“In most cases, translocations occur between chromosomes 11 and 22, leading to the formation of the aberrant EWS-FLI1 chimeric transcription factor [3].”
BackgroundSelf-citationSorensen, P. H. B., Lessnick, S. L., Lopez-Terrada, D., Liu, X. F., Triche, T. J., & Denny, C. T. (1994) · Nature Genetics · doi:10.1038/ng0294-146 · Cited by 747
Nuclear organization of the genome and the potential for gene regulation
Fraser, P., & Bickmore, W. (2007) · Nature · doi:10.1038/nature05916 · Cited by 734 · cited 1×
“In addition, very distant genomic region looping has been demonstrated to promote transcription in transcriptional hubs (reviewed in [49,50]).”
BackgroundScanning Human Gene Deserts for Long-Range Enhancers
Nobrega, M. A., Ovcharenko, I., Afzal, V., & Rubin, E. M. (2003) · Science · doi:10.1126/science.1088328 · Cited by 608 · cited 1×
“Moreover, computational prediction of transcriptional regulatory modules also revealed putative position of transcription factor binding sites far away from coding sequences [47] and gene deserts are now scanned in search for enhancer modules [48].”
BackgroundGenome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data
Jothi, R., Cuddapah, S., Barski, A., Cui, K., & Zhao, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn488 · Cited by 539 · cited 1×
“Since pericentromeric regions are often a source of noise in ChIP-Seq data [35], the corresponding read clusters were removed from subsequent analysis.”
BackgroundMesenchymal Stem Cell Features of Ewing Tumors
Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P., & Delattre, O. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.027 · Cited by 507 · cited 6×
“The expression dataset resulted from previously described EWS-FLI1 inhibition experiments of A673 and SK-N-MC Ewing cell lines [37,40], ranked using the signal-to-noise algorithm.”
BackgroundMethodSelf-citationA variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
Jeon, I. S., Davis, J. N., Braun, B. S., Sublett, J. E., Roussel, M. F., Denny, C. T., & Shapiro, D. N. (1995) · PubMed · Cited by 471
Li, Q., Peterson, K. R., Fang, X., & Stamatoyannopoulos, G. (2002) · Blood · doi:10.1182/blood-2002-04-1104 · Cited by 456
Cited by
Imaging dynamic and selective low-complexity domain interactions that control gene transcription
Chong, S., Dugast-Darzacq, C., Liu, Z., Dong, P., Dailey, G. M., Cattoglio, C., Heckert, A., Banala, S., Lavis, L., Darzacq, X., et al. (2018) · Science · doi:10.1126/science.aar2555 · Cited by 966
“4D), including CAV1, FCGRT,ABHD6,KDSR, and KIAA1797 (33, 39).”
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citationJASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles
Portales-Casamar, E., Thongjuea, S., Kwon, A. T., Arenillas, D., Zhao, X., Valen, E., Yusuf, D., Lenhard, B., Wasserman, W. W., & Sandelin, A. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp950 · Cited by 577
Genomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
“In fact, four or more repeats are necessary for EWS-FLI1 transcriptional activation in reporter assays, and two EWS-FLI1 monomers bind to this four-motif array in biochemical assays (Figure 7) (133, 137, 187).”
InfluentialCancer-Specific Retargeting of BAF Complexes by a Prion-like Domain
Boulay, G., Sandoval, G. J., Riggi, N., Iyer, S., Buisson, R., Naigles, B., Awad, M. E., Rengarajan, S., Volorio, A., McBride, M. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.036 · Cited by 470
“…EWS-FLI1 is able to activate a large set of target genes by operating as a pioneer factor at GGAA microsatellite repeats and inducing active enhancers de novo starting from a closed chromatin conformation (Gangwal et al., 2008; Guillon et al., 2009; Patel et al., 2012; Riggi et al., 2014).”
Riggi, N., Knoechel, B., Gillespie, S. M., Rheinbay, E., Boulay, G., Suvà, M. L., Rossetti, N. E., Boonseng, W. E., Oksuz, O., Cook, E. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.004 · Cited by 445
“GGAA repeats have been implicated previously in Ewing sarcoma on the basis of their association with open chromatin and proximity to some activated genes (Gangwal et al., 2008; Guillon et al., 2009).”
BackgroundAdvances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
“The numbers of bound genomic regions in such studies have varied widel”
Riggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 344
Promiscuous partnerships in Ewing's sarcoma
Sankar, S., & Lessnick, S. L. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.008 · Cited by 258
“These findings were independently validated using next-generation ChIP-sequencing technology (62).”
BackgroundMethodETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors
Oh, S., Shin, S., & Janknecht, R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.02.002 · Cited by 249
“Indeed, it was found that EWS-FLI1, but not FLI1, can also bind to GGAA microsatellite repeats in cells, and transcription of genes regulated by such microsatellites might be important for Ewing tumor genesis [13,83,84].”
BackgroundHOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models
Kulakovskiy, I. V., Vorontsov, I. E., Yevshin, I. S., Soboleva, A. V., Kasianov, A. S., Ashoor, H., Ba-alawi, W., Bajic, V. B., Medvedeva, Y. A., Kolpakov, F. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1249 · Cited by 223
“two clearly different binding subtypes (37).”
Tuning levels of low-complexity domain interactions to modulate endogenous oncogenic transcription
Chong, S., Graham, T. G. W., Dugast-Darzacq, C., Dailey, G. M., Darzacq, X., & Tjian, R. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.007 · Cited by 207
Recent advances in the molecular pathogenesis of Ewing's sarcoma
Toomey, E. C., Schiffman, J. D., & Lessnick, S. L. (2010) · Oncogene · doi:10.1038/onc.2010.205 · Cited by 191
“This result was confirmed by a ChIP-sequencing approach as well (Guillon et al., 2009).”
ResultMolecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional Targets
Lessnick, S. L., & Ladanyi, M. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130237 · Cited by 190
“Genome-wide localization studies using chromatin immunoprecipitation (ChIP) and analyzed with either microarray (chip) or high-throughput sequencing (seq) demonstrated that EWS-FLI1 binds to many GGAA-microsatellites throughout the genome (28, 31).”
BackgroundResultChimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite
Grünewald, T. G. P., Bernard, V., Gilardi-Hebenstreit, P., Raynal, V., Surdez, D., Aynaud, M.-M., Mirabeau, O., Cidre-Aranaz, F., Tirode, F., Zaidi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3363 · Cited by 186
Self-citationBoeva, V. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00024 · Cited by 174
“For instance, this is the case for TFs EWS-FLI1 (Guillon et al., 2009) and NRSF (Johnson et al., 2007; Figure 6).”
BackgroundInfluentialSelf-citationA genomic view of short tandem repeats
Gymrek, M. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.012 · Cited by 181
Aynaud, M.-M., Mirabeau, O., Gruel, N., Grossetête, S., Boeva, V., Durand, S., Surdez, D., Saulnier, O., Zaïdi, S., Gribkova, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.049 · Cited by 171
Self-citationDeep and wide digging for binding motifs in ChIP-Seq data
Kulakovskiy, I. V., Boeva, V. A., Favorov, A. V., & Makeev, V. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq488 · Cited by 156
“Motif lengths were fixed at 21, 12 and 11 for NRSF, GABP and EWS-FLI1, respectively.”
BackgroundMethodInfluentialSelf-citationDr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family
Kovar, H. (2010) · Sarcoma · doi:10.1155/2011/837474 · Cited by 154
Patel, M., Simon, J. M., Iglesia, M. D., Wu, S. B., McFadden, A. W., Lieb, J. D., & Davis, I. J. (2012) · Genome Research · doi:10.1101/gr.125666.111 · Cited by 114
“Genomic localization of each protein was examined by chromatin immunoprecipitation, followed by next-generation sequencing (ChIP-seq) (Supplemental Table 1).”
BackgroundResultInfluentialOncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
Bilke, S., Schwentner, R., Yang, F., Kauer, M. O., Jug, G., Walker, R. L., Davis, S. R., Zhu, Y. J., Pineda, M. A., Meltzer, P. S., et al. (2013) · Genome Research · doi:10.1101/gr.151340.112 · Cited by 122
“at a distance of several megabases from the closest gene, and in (GGAA)n microsatellites (Gangwal and Lessnick 2008; Guillon et al. 2009).”
BackgroundZhang, H., Hughes, C. S., Li, W., He, J., Surdez, D., El-Naggar, A. M., Cheng, H., Prudova, A., Delaidelli, A., Negri, G. L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1690 · Cited by 124
Self-citationBiomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma
Evola, G., Costarella, L., Pavone, V., Caff, G., Cannavò, L., Sessa, A., Avondo, S., & Sessa, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00150 · Cited by 123
“Together, these results indicate the likely contribution of microsatellite elements to long-distance transcription regulation and to oncogenesis (Guillon et al., 2009).”
BackgroundSurdez, D., Zaïdi, S., Grossetête, S., Laud-Duval, K., Ferre, A. S., Mous, L., Vourc’h, T., Tirode, F., Pierron, G., Raynal, V., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.001 · Cited by 112
Self-citationLong noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis
Marques, M. R., Simpson, D. R., Ngok, S. P., Nieves, B., Ron, C., Siprashvili, Z., Vaka, D., Breese, M. R., Crompton, B. D., Alexe, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72124 · Cited by 105
“Direct activation of gene expression by EWS-FLI1 occurs via binding to a consensus motif near promoters or by binding to a distal microsatellite repeat (57, 58).”
Kinsey, M., Smith, R., Iyer, A. K., McCabe, E. R. B., & Lessnick, S. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1540 · Cited by 97
“Similar findings were also observed between the EWS/FLI gene expression profile and ChIP-chip data sets (17).”
MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor
Franzetti, G.-A., Laud-Duval, K., Bellanger, D., Stern, M., Sastre‐Garau, X., & Delattre, O. (2012) · Oncogene · doi:10.1038/onc.2012.403 · Cited by 101
Self-citationRobin, T. P., Smith, A., McKinsey, E., Reaves, L., Jedlicka, P., & Ford, H. L. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0086 · Cited by 91
“Additionally, EWS/FLI1 often regulates critical target genes via GGAA microsatellite repeats (33, 43).”
BackgroundOrth, M. F., Surdez, D., Faehling, T., Ehlers, A. C., Marchetto, A., Grossetête, S., Volckmann, R., Zwijnenburg, D. A., Gerke, J. S., Zaïdi, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111761 · Cited by 92
Self-citationGenome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages
Pehkonen, P., Welter-Stahl, L., Diwo, J., Ryynänen, J., Wienecke-Baldacchino, A., Heikkinen, S., Treuter, E., Steffensen, K. R., & Carlberg, C. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-50 · Cited by 84
“The EWSR1-FLI1 matrix also represents a binding site for ETS-type transcription factors with various functions, such as cell cycle regulation and cell migration [28].”
BackgroundLin, L., Huang, M., Shi, X., Mayakonda, A., Hu, K., Jiang, Y., Guo, X., Chen, L., Pang, B., Doan, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1207 · Cited by 86
“Moreover, GGAA repeats, the established active EWS-FLI1 binding motif in Ewing sarcoma (4,6,24,25), were enriched in a much higher degree in superenhancer regions relative to typical-enhancer ones (Figure 3E).”
BackgroundJohnson, K. M., Mahler, N., Saund, R. S., Theisen, E. R., Taslim, C., Callender, N. W., Crow, J. C., Miller, K. R., & Lessnick, S. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701872114 · Cited by 90
“We, and others, previously demonstrated the enrichment of GGAA-microsatellites near EWS/FLI-regulated target genes (9, 10).”
BackgroundEwing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and Related Tumors
Tsokos, M., Alaggio, R., Dehner, L. P., & Dickman, P. S. (2012) · Pediatric and Developmental Pathology · doi:10.2350/11-08-1078-pb.1 · Cited by 88
“EWS/FLI-1 regulates its target genes by binding to consensus ETS motifs [143,147,148] or specific microsatellite sequences [149,150] and also by mechanisms not involving DNA binding and possibly related to RNA processing [145].”
BackgroundThe molecular pathogenesis of Ewing sarcoma
Mackintosh, C., Madoz‐Gúrpide, J., Ordóñez, J. L., Osuna, D., & Herrero‐Martín, D. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.9.11511 · Cited by 86
Aryee, D. N. T., Niedan, S., Kauer, M., Schwentner, R., Bennani-Baiti, I. M., Ban, J., Muehlbacher, K., Kreppel, M., Walker, R. L., Meltzer, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4333 · Cited by 71
Machiela, M. J., Grünewald, T. G. P., Surdez, D., Reynaud, S., Mirabeau, O., Karlins, E., Rubío, R. A., Zaïdi, S., Grossetête, S., Ballet, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05537-2 · Cited by 76
Self-citationEWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma
Cidre‐Aranaz, F., & Alonso, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00162 · Cited by 78
“Several biochemical studies demonstrated a relationship between the number of GGAA repeats and the degree of promoter activation, indicating that it was necessary a minimum of nine repeats to obtain a response to EWS/FLI1 (30).”
BackgroundBoeva, V., Surdez, D., Guillon, N., Tirode, F., Fejes, A. P., Delattre, O., & Barillot, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq217 · Cited by 89
“The MICSA package was also used on our ChIP-Seq data (16).”
BackgroundMethodInfluentialSelf-citationBoulay, G., Volorio, A., Iyer, S., Broye, L. C., Stamenkovic, I., Riggi, N., & Rivera, M. N. (2018) · Genes & Development · doi:10.1101/gad.315192.118 · Cited by 79
“…repeats where the fusion protein behaves as a pioneer factor to induce chromatin opening and the deposition of histone modifications associated with active enhancer elements (H3K4me1 and H3K27ac) (Gangwal et al. 2008; Guillon et al. 2009; Riggi et al. 2014; Tomazou et al. 2015; Boulay et al. 2017).”
BackgroundFET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex
Lindén, M., Thomsen, C., Grundevik, P., Jonasson, E., Andersson, D., Runnberg, R., Dolatabadi, S., Vannas, C., Santamaría, M. L., Fagman, H., et al. (2019) · EMBO Reports · doi:10.15252/embr.201845766 · Cited by 81
“In contrast, EWSR1-FII1 may bind tens of thousands potential DNA-binding sites in the genome [51,52], and the resulting SWI/SNF recruitment and activation of enhancers in these sites are considered an important part of the oncogenic mechanism.”
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
Musa, J., Cidre-Aranaz, F., Aynaud, M.-M., Orth, M. F., Knott, M. M. L., Mirabeau, O., Mazor, G., Varon, M., Hölting, T. L. B., Grossetête, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12071-2 · Cited by 66
Self-citationTargeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-β Abolishes Ewing Sarcoma Growth
Surdez, D., Benetkiewicz, M., Perrin, V., Han, Z., Pierron, G., Ballet, S., Lamoureux, F., Rédiní, F., Decouvelaere, A., Daudigeos‐Dubus, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0371 · Cited by 80
Self-citationIdentification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor
Osgood, C. L., Maloney, N., Kidd, C. G., Kitchen-Goosen, S. M., Segars, L. E., Gebregiorgis, M., Woldemichael, G. M., He, M., Sankar, S., Lessnick, S. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2624 · Cited by 73
“Therefore, we randomly selected a panel of EWS-FLI1 target genes to reflect both direct and indirect targets established by both genome-wide techniques and specific dedicated studies (see Supplementary Table S2 for evidence, S1 for primers)(11, 12, 24, 27-45).”
MethodSand, L. G. L., Szuhai, K., & Hogendoorn, P. C. W. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716176 · Cited by 84
“[34] FLI1 ChIP-seq Illumina 1G A673, SKNMC cell line not accessible”
BackgroundMethodDownstream EWS/FLI1 - upstream Ewing's sarcoma
Kovar, H. (2010) · Genome Medicine · doi:10.1186/gm129 · Cited by 73
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7124 · Cited by 70
“2, CAV1, GSTM4, and NR0B1 are regulated through EWS-FLI activity at nearby microsatellites, though none are currently candidates for therapeutic development [26, 30, 140-142].”
BackgroundKovar, H. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.947963 · Cited by 72
Genetic Predisposition to Solid Pediatric Cancers
Capasso, M., Montella, A., Tirelli, M., Maiorino, T., Cantalupo, S., & Iolascon, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590033 · Cited by 74
Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma
Gangwal, K., Close, D., Enriquez, C. A., Hill, C. P., & Lessnick, S. L. (2010) · Genes & Cancer · doi:10.1177/1947601910361495 · Cited by 67
“These elements are unusual as they do not conform to the previously described “high-affinity” or “divergent” ETS binding sites, and they demonstrate a unique length dependence to their function.(23,24,28,29) For example, DNA binding and transcriptional activity of EWS/FLI was not observed with 1, 2, or 3 consecutive G…”
Johnson, K. M., Taslim, C., Saund, R. S., & Lessnick, S. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186275 · Cited by 70
Marchetto, A., Ohmura, S., Orth, M. F., Knott, M. M. L., Colombo, M. V., Arrigoni, C., Bardinet, V., Saucier, D., Wehweck, F. S., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16244-2 · Cited by 73
Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis
Stoll, G., Surdez, D., Tirode, F., Laud, K., Barillot, E., Zinovyev, A. Y., & Delattre, O. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt678 · Cited by 59
Self-citationEWS/FLI1 Oncogene Activates Caspase 3 Transcription and Triggers Apoptosis In vivo
Sohn, E. J., Li, K., Reidy, K. T., Beers, L. F., Christensen, B. L., & Lee, S. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1993 · Cited by 62
“To determine whether EWS/FLI1 is present on the human CASP3 promoter in vivo, we performed ChIP experiment using the anti-FLI1 antibody (C-19), which has been previously used for ChIP assay (18, 19).”
MethodLoganathan, S. N., Tang, N., Fleming, J. T., Ma, Y., Guo, Y. P., Borinstein, S. C., Chiang, C. C., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9762 · Cited by 55
Vohra, M., Sharma, A. R., Prabhu, N. B., & Padmalatha, S. (2020) · Public Health Genomics · doi:10.1159/000510253 · Cited by 56
Lu, D. Y., Ellegast, J. M., Ross, K. N., Malone, C. F., Lin, S., Mabe, N. W., Dharia, N. V., Meyer, A., Conway, A. S., Su, A. H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01059-8 · Cited by 57
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma
Fadul, J., Bell, R. N., Hoffman, L. M., Beckerle, M. C., Engel, M. E., & Lessnick, S. L. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.57 · Cited by 47
“We have previously shown that EWS/FLI is able to directly activate genes by binding GGAA microsatellite-rich promoters, while others demonstrated its binding with the transcriptional co-activator CBP/p300, or phosphorylation-dependent interaction with the C-terminal domain of RNA PolII itself [6-12].”
BackgroundSanalkumar, R., Dong, R., Lee, L., Xing, Y., Iyer, S., Letovanec, I., Rosa, S. L., Finzi, G., Musolino, E., Papait, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo3789 · Cited by 43
“EWS-FLI1 is recognized as the main oncogenic driver of this malignancy and has been shown to behave as a powerful aberrant TF that remodels the epigenetic landscape of permissive cells, resulting in their transformation ( 35 – 38 ).”
Ewing sarcoma from molecular biology to the clinic
Dupuy, M., Lamoureux, F., Mullard, M., Postec, A., Regnier, L., Baud’huin, M., Georges, S., Royer, B. B.-L., Ory, B., Rédiní, F., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1248753 · Cited by 53
Oncostatin M Is a Growth Factor for Ewing Sarcoma
David, E., Tirode, F., Baud’huin, M., Guihard, P. J., Laud, K., Delattre, O., Heymann, M., Heymann, D., Rédiní, F., & Blanchard, F. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.07.023 · Cited by 43
Self-citationVibert, J., Saulnier, O., Collin, C., Petit, F., Borgman, K. J. E., Vigneau, J., Gautier, M., Zaïdi, S., Pierron, G., Watson, S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.019 · Cited by 45
Self-citationBeck, R. J., Monument, M. J., Watkins, W. S., Smith, R. A., Boucher, K. M., Schiffman, J. D., Jorde, L. B., Randall, R. L., & Lessnick, S. L. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.04.004 · Cited by 55
“The NR0B1 promoter is the most highly EWS/FLI-bound sequence (21-23) and aberrant expression of this orphan nuclear receptor is absolutely necessary for maintenance of oncogenic transformation in patient-derived Ewing sarcoma cell lines, characterized by anchorage independent growth, and xenograft tumor formation (19,…”
BackgroundMethodInfluentialPerry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
“…operates as a pioneer factor by binding to GGAA microsatellite repeats in closed chromatin and inducing de novo enhancers that can then interact with promoters to activate the transcription of Ewing-specific genes (Gangwal et al. 2008,Gomez et al. 2016,Guillon et al. 2009, Riggi et al. 2014).”
BackgroundReview: Ewing Sarcoma Predisposition
Gargallo, P., Yáñez, Y., Juan, A. D., Segura, V., Balaguer, J., Torres, B., Oltra, S., Castel, V., & Cañete, A. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00765-3 · Cited by 47
McBride, M. J., & Kadoch, C. (2018) · The Journal of Pathology · doi:10.1002/path.5042 · Cited by 45
Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
Vasileva, E., Warren, M., Triche, T. J., & Amatruda, J. F. (2022) · eLife · doi:10.7554/elife.69734 · Cited by 41
Monument, M. J., Johnson, K. M., McIlvaine, E. J., Abegglen, L. M., Watkins, W. S., Jorde, L. B., Womer, R. B., Beeler, N., Monovich, L., Lawlor, E. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104378 · Cited by 46
“Forty to fifty percent of genomic EWS/FLI binding sites are associated with these GGAA-microsatellites [7] and EWS/FLImediated DNA binding and gene expression is dependent on these repetitive GGAA response elements [5,8,9].”
BackgroundThe Role of Phase-Separated Condensates in Fusion Oncoprotein–Driven Cancers
Shirnekhi, H. K., Chandra, B., & Kriwacki, R. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-122050 · Cited by 40
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 42
“Further, silencing of EWS/FLI has been linked to widespread epigenetic reprogramming in multiple studies [23,114,115].”
BackgroundFish, A. E., Chen, L., & Capra, J. A. (2017) · Genome Biology and Evolution · doi:10.1093/gbe/evx194 · Cited by 44
ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation
Gao, Y., He, X., Wu, X., Huang, Y., Toneyan, S., Ha, T., Ipsaro, J. J., Koo, P. K., Joshua‐Tor, L., Bailey, K. M., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01060-1 · Cited by 46
Theisen, E. R., Selich‐Anderson, J., Miller, K. R., Tanner, J. M., Taslim, C., Pishas, K. I., Sharma, S., & Lessnick, S. L. (2020) · Epigenetics · doi:10.1080/15592294.2020.1805678 · Cited by 34
Recent Advances in Pediatric Cancer Research
McEachron, T. A., & Helman, L. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1191 · Cited by 40
“GGAA repeats are the known EWS–FLI1 binding motif in Ewing sarcoma (122).”
BackgroundKim, Y. R., Joo, J., Lee, H. J., Kim, C., Park, J.-C., Yu, Y. S., Kim, C. R., Lee, D. H., Cha, J., Kwon, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51050-0 · Cited by 38
“4d) 30,31 .”
Sánchez-Molina, S., Figuerola-Bou, E., Blanco, E., Sánchez-Jiménez, M., Táboas, P., Gómez‐González, S., Ballaré, C., García-Domínguez, D. J., Prada, E., Hontecillas‐Prieto, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba3058 · Cited by 33
“A decade ago, EWSR1-FLI1 was found to bind preferentially to DNA sites containing GGAA microsatellite repeats (8, 9).”
BackgroundEnglerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells
Caropreso, V., Darvishi, E., Turbyville, T. J., Ratnayake, R., Grohar, P. J., McMahon, J. B., & Woldemichael, G. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701375 · Cited by 32
Targeting metastasis in paediatric bone sarcomas
Bull, E. C., Singh, A., Harden, A. M., Soanes, K., Habash, H., Toracchio, L., Carrabotta, M., Schreck, C., Shah, K. M., Riestra, P. V., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02365-z · Cited by 42
“These neoen-hancers appear to contribute to tumorigenesis and eventually tumour progression and possibly underlie germline variation [28–36].”
Max, D., Hesse, M., Volkmer, I., & Staege, M. S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01347.x · Cited by 36
(mis)-Targeting of SWI/SNF complex(es) in cancer
Reddy, D., Bhattacharya, S., & Workman, J. L. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10102-5 · Cited by 31
Showpnil, I. A., Miller, K. R., Taslim, C., Pishas, K. I., Lessnick, S. L., & Theisen, E. R. (2020) · Journal of Visualized Experiments · doi:10.3791/61564 · Cited by 30
Yasir, M., Park, J., & Chun, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015173 · Cited by 31
“…like Caveolin-1 (CAV1) [84], glutathione S-transferase M4 (GSTM4) [85], FCGRT (Fc fragment of IgG, receptor, transporter, alpha), FVT1/KDSR (3-ketodihydrosphingosine reductase) or ABHD6 (Abhydrolase Domain-Containing Protein) [86], highlighting the broader implications of this regulatory mechanism.”
Saulnier, O., Guedri, K., Aynaud, M.-M., Chakraborty, A., Bruyr, J., Pineau, J., O’Grady, T. M., Mirabeau, O., Grossetête, S., Galvan, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab305 · Cited by 30
Self-citationTruong, D. D., Lamhamedi-Cherradi, S.-E., Porter, R. W., Krishnan, S., Swaminathan, J., Gibson, A., Lazar, A. J., Livingston, J. A., Gopalakrishnan, V., Gordon, N. B., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10977-1 · Cited by 28
RUNX3 Facilitates Growth of Ewing Sarcoma Cells
Bledsoe, K. L., McGee‐Lawrence, M. E., Camilleri, E. T., Wang, X., Riester, S. M., van Wijnen, A. J., Oliveira, A. M., & Westendorf, J. J. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24663 · Cited by 25
Uchiumi, F., Miyazaki, S., & Tanuma, S.-I. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0674-x · Cited by 31
“The GGAA-containing microsatellites are located in the promoter regions of the DAX1/NR0B1, FCGRT, CAV1, CACNB2, FEZF1, KIAA1797, and GSTM4 genes [43, 45, 46].”
BackgroundTheisen, E. R., Miller, K. R., Showpnil, I. A., Taslim, C., Pishas, K. I., & Lessnick, S. L. (2019) · Genes & Cancer · doi:10.18632/genesandcancer.188 · Cited by 27
“The EWS portion also confers novel DNA binding properties to FLI, such that the fusion binds repetitive GGAA-microsatellites [11-13].”
BackgroundBuchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaïdi, S., Gentric, G., Corbé, M., Müller, K., Nery, E. D., Surdez, D., et al. (2022) · Cancers · doi:10.3390/cancers14092327 · Cited by 27
Self-citationTargeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 27
“It regulates multiple proteins through its prion-like domain to tumor-specific enhancers and promotors, recruiting acetyltransferases and establishing de novo enhancers by generating H3K27ac, thus opening the chromosomal architecture, which contributes to the activation of target genes [29,30,37,39].”
BackgroundEWS ‐ FLI 1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma
Shimizu, R., Tanaka, M., Tsutsumi, S., Aburatani, H., Yamazaki, Y., Homme, M., Kitagawa, Y., & Nakamura, T. (2018) · Cancer Science · doi:10.1111/cas.13710 · Cited by 27
“Previous studies showed that EWS‐FLI1 binds to both canonical Ets binding sites and GGAA microsatellites to regulate downstream target genes.(4,12,13) Notably, GGAA microsatellite‐associated EWS‐ FLI1‐binding sites are frequently linked to active enhancers and show drastic transactivation by EWS‐FLI1, thus emphasizing…”
BackgroundFlores, G., Everett, J. H., Boguslawski, E. A., Oswald, B. M., Madaj, Z., Beddows, I., Dikalov, S., Adams, M., Klumpp-Thomas, C. A., Kitchen-Goosen, S. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0775 · Cited by 32
“Indeed, both FLI1 and EWS-FLI1 can bind the promoter GGAA EWS-FLI1 response element but only EWS-FLI1 can transactivate (6).”
BackgroundEWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival
Gallegos, Z. R., Taus, P., Gibbs, Z. A., McGlynn, K., Gomez, N. C., Davis, I. J., & Whitehurst, A. W. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00138-19 · Cited by 25
Goodspeed, A. E., Bodlak, A., Duffy, A. B., Nelson-Taylor, S., Oike, N., Porfilio, T. E., Shirai, R., Walker, D., Treece, A., Black, J. O., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2040 · Cited by 23
Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications
Yu, L., Davis, I. J., & Liu, P. (2023) · Cancers · doi:10.3390/cancers15020382 · Cited by 27
Origin of Ewing sarcoma by embryonic reprogramming of neural crest to mesoderm
Vasileva, E., Arata, C., Luo, Y., Burgos, R., Crump, J. G., & Amatruda, J. F. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116376 · Cited by 26
Li, M., & Chen, C.-W. D. (2022) · Biomedicines · doi:10.3390/biomedicines10061325 · Cited by 25
“For example, ChIP-seq(chromatin immunoprecipitation coupled with high throughput sequencing)based epigenetic profiling has been conducted to investigate how EWSR1-FLI1 binds to chromatin [19,20] and how EWSR1-FLI1 establishes n appropriate chromatin state for gene expression [21,22].”
BackgroundInfluentialPolit, L., Kerdivel, G., Gregoricchio, S., Esposito, M., Guillouf, C., & Boeva, V. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04320-3 · Cited by 28
Self-citationAbundance, arrangement, and function of sequence motifs in the chicken promoters
Abe, H., & Gemmell, N. J. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-900 · Cited by 26
“For example, the EWS/FLI protein, which belongs to EST-type transcription factor (TF), directly binds to GGAA-motifs in the glutathione S-transferase M4 promoter, and transcriptional activity is highly dependent upon the number of repeats [12-14].”
Phase separation of the oncogenic fusion protein EWS::FLI1 is modulated by its DNA-binding domain
Selig, E. E., Sohn, E. J., Stoja, A. P., Moreno-Romero, A. K., Akula, S., Xu, X., Bishop, A. J. R., & Libich, D. S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221823122 · Cited by 26
“A double - stranded DNA oligonucleotide containing 10 GGAA (GGAA 10 ) repeats known to bind FLI1 DBD in vitro (14, 47), exerted the same effect on EWS::FLI1 aggregation ( SI Appendix , Fig.”
Regulation of Metastasis in Ewing Sarcoma
Li, M., & Chen, C.-W. D. (2022) · Cancers · doi:10.3390/cancers14194902 · Cited by 23
Metadata
- Authors
- Guillon, N., Tirode, F., Boeva, V., Zynovyev, A., Barillot, E., & Delattre, O.
- Affiliations
- Inserm (FR)
- Corresponding author
- Delattre, Olivier
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-23
- Volume
- 4
- Issue
- 3
- Pages
- e4932
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2654724
- OpenAlex
- W2108696643
- Cited by
- 218
- References
- 55
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 16 · 2020: 16 · 2019: 7 · 2018: 11 · 2017: 10 · 2016: 6 · 2015: 9 · 2014: 10 · 2013: 7 · 2012: 14
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2022-06-23)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- EWS-FLI1, Ewing sarcoma, ETS transcription factors, transcriptional activation, DNA binding sites, carcinogenesis, ChIP-seq
- MeSH terms
- Adolescent, Base Sequence, Gene Expression Regulation, Humans, Sarcoma, Ewing, Transcription Factors, Oncogene Proteins, Fusion, Transcriptional Activation, Microsatellite Repeats, RNA-Binding Protein EWS, Proto-Oncogene Protein c-fli-1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.